The accreditors of this session require that you periodically check in to verify that you are still attentive.
Please click the button below to indicate that you are.
METABOLIC OUTCOMES AND KEY EFFICACY DATA FROM A PHASE 2 TRIAL EVALUATING COMBINATION OBETICHOLIC ACID AND BEZAFIBRATE IN PATIENTS WITH PRIMARY BILIARY CHOLANGITIS
EFFECT OF OBETICHOLIC ACID ON APRI SCORE IN PATIENTS AT HIGHER RISK FOR FIBROSIS, AS DETERMINED BY HIGHER BASELINE FIBROSIS-4 SCORE AND LIVER STIFFNESS: SUBANALYSIS OF THE PHASE 3 POISE TRIAL IN PRIMARY BILIARY CHOLANGITIS
MULTI-OMIC SEQUENCING REVEALS DISTINCTIVE GENE EXPRESSION AND DNA METHYLATION ALTERATIONS AS POTENTIAL PREDICTORS OF PRIMARY SCLEROSING CHOLANGITIS DEVELOPMENT IN TREATMENT-NAÏVE PAEDIATRIC ULCERATIVE COLITIS
METABOLIC BIOMARKERS PREDICT THE OUTCOME OF UDCA TREATMENT ON PBC PATIENTS WITH HIGH ACCURACY
PATHOLOGICAL CHARACTERISTICS AND ROLE OF PLASMA CELLS IN REFRACTORY PRIMARY BILIARY CHOLANGITIS: IMPLICATIONS FOR TARGETED THERAPY
FOLIC ACID DEFICIENCY EXACERBATES BILIARY INFLAMMATION IN PRIMARY BILIARY CHOLANGITIS BY PROMOTING CHOLANGIOCYTE SENESCENCE